Last edition
News about "Akeso "
US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer
The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.
Akeso | 12/12/2025 | By Akanki | 107
Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer
COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.
Akeso | 15/09/2025 | By Dineshwori | 166
Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer
With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.
Akeso | 17/03/2025 | By Aishwarya | 386
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy